FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:PCLO-CDK14

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: PCLO-CDK14
FusionPDB ID: 63329
FusionGDB2.0 ID: 63329
HgeneTgene
Gene symbol

PCLO

CDK14

Gene ID

27445

5218

Gene namepiccolo presynaptic cytomatrix proteincyclin dependent kinase 14
SynonymsACZ|PCH3PFTAIRE1|PFTK1
Cytomap

7q21.11

7q21.13

Type of geneprotein-codingprotein-coding
Descriptionprotein piccoloaczonincyclin-dependent kinase 14PFTAIRE protein kinase 1cell division protein kinase 14serine/threonine-protein kinase PFTAIRE-1
Modification date2020031320200313
UniProtAcc.

O94921

Main function of 5'-partner protein: FUNCTION: Serine/threonine-protein kinase involved in the control of the eukaryotic cell cycle, whose activity is controlled by an associated cyclin. Acts as a cell-cycle regulator of Wnt signaling pathway during G2/M phase by mediating the phosphorylation of LRP6 at 'Ser-1490', leading to the activation of the Wnt signaling pathway. Acts as a regulator of cell cycle progression and cell proliferation via its interaction with CCDN3. Phosphorylates RB1 in vitro, however the relevance of such result remains to be confirmed in vivo. May also play a role in meiosis, neuron differentiation and may indirectly act as a negative regulator of insulin-responsive glucose transport. {ECO:0000269|PubMed:16461467, ECO:0000269|PubMed:17517622, ECO:0000269|PubMed:19524571, ECO:0000269|PubMed:20059949}.
Ensembl transtripts involved in fusion geneENST idsENST00000333891, ENST00000423517, 
ENST00000426442, ENST00000437081, 
ENST00000436577, ENST00000496279, 
ENST00000265741, ENST00000380050, 
ENST00000406263, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score4 X 5 X 3=6022 X 24 X 12=6336
# samples 532
** MAII scorelog2(5/60*10)=-0.263034405833794
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(32/6336*10)=-4.30742852519225
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: PCLO [Title/Abstract] AND CDK14 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: PCLO [Title/Abstract] AND CDK14 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)PCLO(82595087)-CDK14(90376996), # samples:2
Anticipated loss of major functional domain due to fusion event.PCLO-CDK14 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PCLO-CDK14 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PCLO-CDK14 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PCLO-CDK14 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneCDK14

GO:0000086

G2/M transition of mitotic cell cycle

20059949

TgeneCDK14

GO:0060828

regulation of canonical Wnt signaling pathway

20059949



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:82595087/chr7:90376996)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across PCLO (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across CDK14 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000333891PCLOchr782595087-ENST00000380050CDK14chr790376996+8850435533853951685
ENST00000333891PCLOchr782595087-ENST00000265741CDK14chr790376996+8849435533853951685
ENST00000333891PCLOchr782595087-ENST00000406263CDK14chr790376996+8845435533853951685
ENST00000423517PCLOchr782595087-ENST00000380050CDK14chr790376996+8850435533853951685
ENST00000423517PCLOchr782595087-ENST00000265741CDK14chr790376996+8849435533853951685
ENST00000423517PCLOchr782595087-ENST00000406263CDK14chr790376996+8845435533853951685
ENST00000333891PCLOchr782595086-ENST00000380050CDK14chr790376995+8850435533853951685
ENST00000333891PCLOchr782595086-ENST00000265741CDK14chr790376995+8849435533853951685
ENST00000333891PCLOchr782595086-ENST00000406263CDK14chr790376995+8845435533853951685
ENST00000423517PCLOchr782595086-ENST00000380050CDK14chr790376995+8850435533853951685
ENST00000423517PCLOchr782595086-ENST00000265741CDK14chr790376995+8849435533853951685
ENST00000423517PCLOchr782595086-ENST00000406263CDK14chr790376995+8845435533853951685

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000333891ENST00000380050PCLOchr782595087-CDK14chr790376996+0.0008780360.99912196
ENST00000333891ENST00000265741PCLOchr782595087-CDK14chr790376996+0.0008774040.99912256
ENST00000333891ENST00000406263PCLOchr782595087-CDK14chr790376996+0.0008804980.99911946
ENST00000423517ENST00000380050PCLOchr782595087-CDK14chr790376996+0.0008780360.99912196
ENST00000423517ENST00000265741PCLOchr782595087-CDK14chr790376996+0.0008774040.99912256
ENST00000423517ENST00000406263PCLOchr782595087-CDK14chr790376996+0.0008804980.99911946
ENST00000333891ENST00000380050PCLOchr782595086-CDK14chr790376995+0.0008780360.99912196
ENST00000333891ENST00000265741PCLOchr782595086-CDK14chr790376995+0.0008774040.99912256
ENST00000333891ENST00000406263PCLOchr782595086-CDK14chr790376995+0.0008804980.99911946
ENST00000423517ENST00000380050PCLOchr782595086-CDK14chr790376995+0.0008780360.99912196
ENST00000423517ENST00000265741PCLOchr782595086-CDK14chr790376995+0.0008774040.99912256
ENST00000423517ENST00000406263PCLOchr782595086-CDK14chr790376995+0.0008804980.99911946

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PCLO-CDK14

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
PCLOchr782595086CDK14chr79037699543551339AKPDQVEPGKEKTPTSPKFGKADSYE
PCLOchr782595087CDK14chr79037699643551339AKPDQVEPGKEKTPTSPKFGKADSYE

Top

Potential FusionNeoAntigen Information of PCLO-CDK14 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PCLO-CDK14_82595086_90376995.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PCLO-CDK14chr782595086chr7903769954355HLA-B57:03KTPTSPKF0.99810.97841119
PCLO-CDK14chr782595086chr7903769954355HLA-B50:01KEKTPTSP0.98210.7575917
PCLO-CDK14chr782595086chr7903769954355HLA-B38:02EKTPTSPKF0.4880.95541019
PCLO-CDK14chr782595086chr7903769954355HLA-B15:10EKTPTSPKF0.15270.67481019
PCLO-CDK14chr782595086chr7903769954355HLA-B15:18EKTPTSPKF0.10580.78151019
PCLO-CDK14chr782595086chr7903769954355HLA-B15:37EKTPTSPKF0.01830.7131019
PCLO-CDK14chr782595086chr7903769954355HLA-A30:08KTPTSPKFGK0.99560.59311121
PCLO-CDK14chr782595086chr7903769954355HLA-B47:01KEKTPTSPKF0.98690.5792919
PCLO-CDK14chr782595086chr7903769954355HLA-B44:03KEKTPTSPKF0.98160.9467919
PCLO-CDK14chr782595086chr7903769954355HLA-B15:03KEKTPTSPKF0.91650.93919
PCLO-CDK14chr782595086chr7903769954355HLA-B58:06KTPTSPKF0.99880.82741119
PCLO-CDK14chr782595086chr7903769954355HLA-B57:02KTPTSPKF0.99640.85181119
PCLO-CDK14chr782595086chr7903769954355HLA-B50:04KEKTPTSP0.98210.7575917
PCLO-CDK14chr782595086chr7903769954355HLA-B50:05KEKTPTSP0.98210.7575917
PCLO-CDK14chr782595086chr7903769954355HLA-A30:01KEKTPTSPK0.98360.8872918
PCLO-CDK14chr782595086chr7903769954355HLA-B48:02EKTPTSPKF0.2510.83571019
PCLO-CDK14chr782595086chr7903769954355HLA-A30:01KTPTSPKFGK0.99550.7351121
PCLO-CDK14chr782595086chr7903769954355HLA-B15:53KEKTPTSPKF0.99270.9604919
PCLO-CDK14chr782595086chr7903769954355HLA-B15:68KEKTPTSPKF0.99140.8216919
PCLO-CDK14chr782595086chr7903769954355HLA-B15:54KEKTPTSPKF0.9830.9579919
PCLO-CDK14chr782595086chr7903769954355HLA-B44:07KEKTPTSPKF0.98160.9467919
PCLO-CDK14chr782595086chr7903769954355HLA-B44:13KEKTPTSPKF0.98160.9467919
PCLO-CDK14chr782595086chr7903769954355HLA-B44:26KEKTPTSPKF0.98160.9467919
PCLO-CDK14chr782595086chr7903769954355HLA-B48:02KEKTPTSPKF0.90020.9343919
PCLO-CDK14chr782595086chr7903769954355HLA-B41:03KEKTPTSPKF0.74140.6007919

Top

Potential FusionNeoAntigen Information of PCLO-CDK14 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of PCLO-CDK14

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
2009EPGKEKTPTSPKFGPCLOCDK14chr782595086chr7903769954355

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PCLO-CDK14

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN2009EPGKEKTPTSPKFG-7.9962-8.1096
HLA-B14:023BVN2009EPGKEKTPTSPKFG-5.70842-6.74372
HLA-B52:013W392009EPGKEKTPTSPKFG-6.83737-6.95077
HLA-B52:013W392009EPGKEKTPTSPKFG-4.4836-5.5189
HLA-A11:014UQ22009EPGKEKTPTSPKFG-10.0067-10.1201
HLA-A11:014UQ22009EPGKEKTPTSPKFG-9.03915-10.0745
HLA-A24:025HGA2009EPGKEKTPTSPKFG-6.56204-6.67544
HLA-A24:025HGA2009EPGKEKTPTSPKFG-5.42271-6.45801
HLA-B44:053DX82009EPGKEKTPTSPKFG-7.85648-8.89178
HLA-B44:053DX82009EPGKEKTPTSPKFG-5.3978-5.5112
HLA-A02:016TDR2009EPGKEKTPTSPKFG-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of PCLO-CDK14

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
PCLO-CDK14chr782595086chr7903769951019EKTPTSPKFGAAAAAACACCAACAAGTCCCAAATTT
PCLO-CDK14chr782595086chr7903769951119KTPTSPKFAAAACACCAACAAGTCCCAAATTT
PCLO-CDK14chr782595086chr7903769951121KTPTSPKFGKAAAACACCAACAAGTCCCAAATTTGGAAAA
PCLO-CDK14chr782595086chr790376995917KEKTPTSPAAAGAAAAAACACCAACAAGTCCC
PCLO-CDK14chr782595086chr790376995918KEKTPTSPKAAAGAAAAAACACCAACAAGTCCCAAA
PCLO-CDK14chr782595086chr790376995919KEKTPTSPKFAAAGAAAAAACACCAACAAGTCCCAAATTT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of PCLO-CDK14

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADPCLO-CDK14chr782595086ENST00000333891chr790376995ENST00000265741TCGA-D7-A6EX

Top

Potential target of CAR-T therapy development for PCLO-CDK14

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to PCLO-CDK14

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to PCLO-CDK14

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource